John G Ullman & Associates Inc. Sells 3,208 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• John G Ullman & Associates Inc. sold 3,208 shares of Jazz Pharmaceuticals, reducing its stake by 8.2% to 35,910 shares valued at approximately $3.81 million.
• Analysts have set new price targets for Jazz Pharmaceuticals, with Goldman Sachs raising their target from $162.00 to $185.00 while Needham & Company issued a target of $202.00.
• Jazz Pharmaceuticals reported a significant earnings miss, with a reported loss of ($8.25) per share, compared to analysts' estimates of ($5.61).

John G Ullman & Associates Inc. reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 8.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,910 shares of the specialty pharmaceutical company's stock after selling 3,208 shares during the quarter. John G Ullman & Associates Inc. owned about 0.06% of Jazz Pharmaceuticals worth $3,811,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Kendall Capital Management boosted its position in shares of Jazz Pharmaceuticals by 1.2% in the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock worth $989,000 after purchasing an additional 95 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Jazz Pharmaceuticals by 0.6% in the 1st quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock worth $2,098,000 after purchasing an additional 100 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its position in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company's stock worth $1,046,000 after purchasing an additional 110 shares in the last quarter. Assetmark Inc. boosted its position in shares of Jazz Pharmaceuticals by 16.0% in the 1st quarter. Assetmark Inc. now owns 843 shares of the specialty pharmaceutical company's stock worth $105,000 after purchasing an additional 116 shares in the last quarter. Finally, Covestor Ltd boosted its position in shares of Jazz Pharmaceuticals by 12.8% in the 1st quarter. Covestor Ltd now owns 1,163 shares of the specialty pharmaceutical company's stock worth $145,000 after purchasing an additional 132 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

JAZZ has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price target on the stock. The Goldman Sachs Group upped their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research report on Friday, August 29th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Royal Bank Of Canada upped their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $178.93.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $136.06 on Friday. The firm has a market cap of $8.25 billion, a PE ratio of -20.22, a P/E/G ratio of 8.35 and a beta of 0.28. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The firm has a fifty day simple moving average of $128.20 and a two-hundred day simple moving average of $116.00. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. Jazz Pharmaceuticals's quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of the business's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total transaction of $490,000.00. Following the completion of the sale, the director directly owned 408,826 shares in the company, valued at approximately $57,235,640. The trade was a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.